For Payers and health plans
Although 30 million Americans have obstructive sleep apnea (OSA), only 20% are diagnosed and treated. Given its negative impact on metabolic, respiratory, mental, and cardiovascular health, the per-capita cost is enormous. In fact, undiagnosed OSA costs Americans over $30 billion per year in increased health care utilization (1).
Regardless of the magnitude of the problem, current approaches to screening, diagnosis, and treatment are not making a meaningful impact. A cost-effective, holistic solution is required… enter DROWZLE®.
OSA Through The Lens of a Population Health Management Framework
Our fundamental goal is to cost-effectively identify individuals with OSA at large enough scale to make a meaningful impact—the 80% who are currently undiagnosed. DROWZLE is the ideal solution, as characterized by the PHM framework.
Better Outcomes
The connection between untreated OSA and other chronic disease is well established. Considering this connection, the treatment of chronic diseases (such as CHF, obesity/metabolic disease, and cardiovascular disease) should include the identification and treatment of comorbid OSA. Integrating OSA into chronic disease management programs is increasingly important with an aging population, particularly as reimbursement shifts from traditional fee-for-service to a model that is based on outcomes and quality.
Lower Costs
The per capita cost to diagnose OSA: Although the polysomnogram (in laboratory PSG) is considered the “gold standard”, it is a costly and largely inaccessible option for most people. The DROWZLE Sleep Health Program is a scalable solution which can lead to cost-effective screening and diagnosis of obstructive sleep apnea (OSA).
The cost of managing co-morbid chronic disease: Undiagnosed and untreated OSA increases the cost burden to treat other co-morbid conditions. As a result, healthcare utilization is estimated to increase by over $30 Billion per year.
An Improved Patient Experience
Patients can now test themselves in their own homes, without the need for sensors or bulky equipment.
Long wait times for sleep tests are eliminated, reducing the time needed for the patient to receive a diagnosis and initiate treatment.
The patient’s out-of-pocket expenses for deductibles and co-pays are lower.
An Improved Clinician Experience
Providers can now efficiently screen patients with chronic conditions for OSA, making disease management programs more comprehensive and effective. Outcomes can be improved and healthcare utilization reduced as more patients are identified and treated.